Home LiteratureArticle Details
PMID: 8637513 Published · ppublish English Comparative Study Journal Article

Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection.

The New England journal of medicine ·Vol. 334 ·No. 26 ·1996-06-27 ·Pages 1691-6

Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, Cheung L, DiBisceglie A, Hoofnagle J, Shih JW

Abstract

For many people infected with the hepatitis C virus (HCV), the route of exposure, risk of transmission, and severity of associated liver disease are unknown. We studied these variables in people who donated blood voluntarily. Blood donors who tested positive for HCV antibodies on enzyme immunoassay were classified according to whether the results of a confirmatory second-generation recombinant immunoblot assay (RIBA) for HCV were positive, negative, or indeterminate. The evaluations also included an assessment of risk factors, a physical examination, serial determinations of alanine aminotransferase levels and HCV serologic assays, a polymerase-chain-reaction assay for HCV RNA, testing of sexual contacts and family members, and liver biopsies in some participants who were HCV-positive by RIBA. A total of 481 donors were studied, among whom 248 were positive for HCV by RIBA, 102 had indeterminate results, and 131 were HCV-negative. In a logistic-regression analysis, significant risk factors for HCV infection among the HCV-positive participants were a history of blood transfusion in 66 (27 percent; P < 0.001 for the comparison with RIBA-negative donors), intranasal cocaine use in 169 (68 percent, P < 0.001), intravenous drug use in 103 (42 percent, P = 0.001), sexual promiscuity in 132 (53 percent, P = 0.002), and ear piercing among men (P < 0.05). Nine of 85 sexual partners of HCV-positive donors were anti-HCV-positive; 8 had used intravenous drugs or received transfusions. HCV RNA was found in 213 HCV-positive donors (86 percent), 3 who had indeterminate results by RIBA (2 of these 3 tested positive with a more specific, third-generation RIBA), and none who were HCV-negative. Of the HCV-positive donors, 69 percent had biochemical evidence of chronic liver disease; among 77 donors positive for HCV by RIBA who underwent liver biopsy, 5 had severe chronic hepatitis or cirrhosis, 66 had mild-to-moderate chronic hepatitis, and 6 had no evidence of hepatitis. Among volunteer blood donors, prior blood transfusion, intranasal cocaine use, intravenous drug use, sexual promiscuity, and ear piercing in men are risk factors for HCV infection. The high frequency of intravenous drug use was unexpected, because these donors had denied such use when questioned directly at the time of their blood donations.

MeSH Terms
Adult Blood Donors Cocaine/administration & dosage Ear, External/surgery Female Hepacivirus/immunology,isolation & purification Hepatitis C/diagnosis,etiology,transmission Hepatitis C Antibodies/blood Humans Immunoblotting Liver Diseases/epidemiology Logistic Models Male Middle Aged RNA, Viral/blood Risk Factors Sexual Behavior Substance Abuse, Intravenous Substance-Related Disorders Viremia/diagnosis
Chemicals
Hepatitis C Antibodies RNA, Viral Cocaine
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Conry-Cantilena C
Department of Transfusion Medicine, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md 20892, USA.
VanRaden M
Gibble J
Melpolder J
Shakil A O
Viladomiu L
Cheung L
DiBisceglie A
Hoofnagle J
Shih J W
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
0028-4793
Published
1996-06-27
Pages
1691-6
Language
English
Region
United States
NLM ID
0255562
Subset
IM
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com